Nemucore was founded and funded by the NIH to understand chemotherapy resistance with the mission to develop methods to overcome resistance in patients suffering with rare, lethal cancers. 

Over the weekend, I had a wonderful opportunity to speak with several highly regarded clinical oncologists at a Conquer Cancer Foundation event.  There was a lot discussion about the promise of immuno-oncology and precision medicine.  However, as the discussions evolved it became quite apparent that one of the big opportunities in cancer therapy is understanding chemotherapy resistance.  With this understanding of resistance, create more effective treatment approaches and essentially placing chemotherapy resistance on a similar level of concern as we currently apply to chemotherapy sensitivity.

During my discussions, it became apparent that these influential oncologists wished that biopharmaceutical companies would spend more time identifying why patients become resistant to chemotherapy and how to circumvent it!  

As one oncologist put it ".....chemotherapy resistance is a major challenge in cancer treatment today as most patients who die from cancer after they acquire resistance to multiple lines of traditional and targeted chemotherapies"

For everyone who has been following Nemucore this should be music to your ears.  Why??

Nemucore's precision medicine program for Acute Myeloid Leukemia (AML) measures signals that make a cancer sensitive and resistant to NMI-900 - exactly what the doctor ordered!

At Nemucore we have always believed that we are on the cutting edge of the next wave of precision medicine innovation with our NMI-900 program but this weekends discussions clearly place us in at the leading edge.

Investors who want to be part of a company at the leading edge of a revolution in precision medicine have until 10/25/2018 to participate in our current offering. 

We hope you will become part of our mission to help people battling AML and other blood cancers!

Best wishes 

Tim